This cross-sectional pilot study published in Kidney360, examined the gut microbiome of 25 patients with autosomal dominant polycystic kidney disease (ADPKD) and 12 matched healthy controls.

Using 16S rRNA sequencing and serum toxin analysis, the study found that patients with ADPKD had a significantly altered gut microbiota, including reduced levels of beneficial Actinobacteria (such as Bifidobacteriaceae) and elevated levels of Enterobacteriaceae.

More severe ADPKD (Mayo Class 1D/1E) was linked to increased Streptococcaceae, while early-onset hypertension (<35 years) was associated with higher Proteobacteria and lower Tannerellaceae. Serum uremic toxin levels were elevated and correlated with worsening kidney function.

Why is this important?

This study highlights a potential connection between gut dysbiosis and ADPKD progression, independent of kidney function. Specific microbiome signatures appear to align with more aggressive disease phenotypes and earlier vascular involvement.

These findings suggest that the gut microbiota may play a role in modifying disease severity in ADPKD and could serve as a novel therapeutic target for slowing progression and improving patient outcomes.

Read Original Article Here ->>